Hyperhomocysteinemia as a risk factor for deep-vein thrombosis

被引:875
作者
denHeijer, M
Koster, T
Blom, HJ
Bos, GMJ
Briet, E
Reitsma, PH
Vandenbroucke, JP
Rosendaal, FR
机构
[1] LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS
[2] LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS
[3] UNIV NIJMEGEN HOSP,LAB PEDIAT & NEUROL,DEPT PEDIAT,6500 HB NIJMEGEN,NETHERLANDS
关键词
D O I
10.1056/NEJM199603213341203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis, To assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels In patients with a first episode of deep-vein thrombosis and in normal control subjects. Methods. We measured plasma homocysteine levels in 269 patients with a first, objectively diagnosed episode of deep-vein thrombosis and in 269 healthy controls matched to the patients according to age and sex, Hyperhomocysteinemia was defined as a plasma homocysteine level above the 95th percentile in the control group (18.5 mu mol per liter). Results. Of the 269 patients, 28 (10 percent) had plasma homocysteine levels above the 95th percentile for the controls, as compared with 13 of the controls (matched odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2), The association between elevated homocysteine levels and venous thrombosis was stronger among women than among men and increased with age, The exclusion of subjects with other established risk factors for thrombosis (e.g., a deficiency of protein C, protein S, or antithrombin; resistance to activated protein C; pregnancy or recent childbirth; or oral-contraceptive use) did not materially affect the risk estimates. Conclusions. High plasma homocysteine levels are a risk factor for deep-vein thrombosis in the general population. (C) 1996, Massachusetts Medical Society.
引用
收藏
页码:759 / 762
页数:4
相关论文
共 25 条
  • [1] MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C
    BERTINA, RM
    KOELEMAN, BPC
    KOSTER, T
    ROSENDAAL, FR
    DIRVEN, RJ
    DERONDE, H
    VANDERVELDEN, PA
    REITSMA, PH
    [J]. NATURE, 1994, 369 (6475) : 64 - 67
  • [2] BIENVENU T, 1991, PRESSE MED, V20, P985
  • [3] PATHOBIOCHEMICAL IMPLICATIONS OF HYPERHOMOCYSTEINEMIA
    BLOM, HJ
    VANDERMOLEN, EF
    [J]. FIBRINOLYSIS, 1994, 8 : 86 - 87
  • [4] HETEROZYGOSITY FOR HOMOCYSTINURIA IN PREMATURE PERIPHERAL AND CEREBRAL OCCLUSIVE ARTERIAL-DISEASE
    BOERS, GHJ
    SMALS, AGH
    TRIJBELS, FJM
    FOWLER, B
    BAKKEREN, JAJM
    SCHOONDERWALDT, HC
    KLEIJER, WJ
    KLOPPENBORG, PWC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (12) : 709 - 715
  • [5] BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51
  • [6] IS HYPERHOMOCYSTEINAEMIA A RISK FACTOR FOR RECURRENT VENOUS THROMBOSIS
    DENHEIJER, M
    BLOM, HJ
    GERRITS, WBJ
    ROSENDAAL, FR
    HAAK, HL
    WIJERMANS, PW
    BOS, GMJ
    [J]. LANCET, 1995, 345 (8954): : 882 - 885
  • [7] DENHEIJER M, 1994, FIBRINOLYSIS S2, V8, P291
  • [8] ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142
  • [9] HIGH PREVALENCE OF HYPERHOMOCYST(E)INEMIA IN PATIENTS WITH JUVENILE VENOUS THROMBOSIS
    FALCON, CR
    CATTANEO, M
    PANZERI, D
    MARTINELLI, I
    MANNUCCI, PM
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (07): : 1080 - 1083
  • [10] FISKERSTRAND T, 1993, CLIN CHEM, V39, P263